S&P 500   3,245.38 (-2.23%)
DOW   26,869.54 (-2.85%)
QQQ   264.36 (-0.94%)
AAPL   107.14 (+0.28%)
MSFT   200.20 (-0.09%)
FB   248.31 (-1.67%)
GOOGL   1,427.35 (-1.64%)
AMZN   2,904.48 (-1.71%)
NVDA   492.99 (+1.11%)
TSLA   444.47 (+0.52%)
BABA   271.13 (-0.47%)
CGC   15.61 (-4.58%)
GE   6.26 (-9.01%)
MU   49.09 (-3.25%)
AMD   76.85 (+2.56%)
T   28.29 (-2.21%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.66 (-2.14%)
NFLX   480.00 (+2.14%)
DIS   124.31 (-3.36%)
BAC   24.12 (-4.32%)
BA   156.69 (-2.76%)
S&P 500   3,245.38 (-2.23%)
DOW   26,869.54 (-2.85%)
QQQ   264.36 (-0.94%)
AAPL   107.14 (+0.28%)
MSFT   200.20 (-0.09%)
FB   248.31 (-1.67%)
GOOGL   1,427.35 (-1.64%)
AMZN   2,904.48 (-1.71%)
NVDA   492.99 (+1.11%)
TSLA   444.47 (+0.52%)
BABA   271.13 (-0.47%)
CGC   15.61 (-4.58%)
GE   6.26 (-9.01%)
MU   49.09 (-3.25%)
AMD   76.85 (+2.56%)
T   28.29 (-2.21%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.66 (-2.14%)
NFLX   480.00 (+2.14%)
DIS   124.31 (-3.36%)
BAC   24.12 (-4.32%)
BA   156.69 (-2.76%)
S&P 500   3,245.38 (-2.23%)
DOW   26,869.54 (-2.85%)
QQQ   264.36 (-0.94%)
AAPL   107.14 (+0.28%)
MSFT   200.20 (-0.09%)
FB   248.31 (-1.67%)
GOOGL   1,427.35 (-1.64%)
AMZN   2,904.48 (-1.71%)
NVDA   492.99 (+1.11%)
TSLA   444.47 (+0.52%)
BABA   271.13 (-0.47%)
CGC   15.61 (-4.58%)
GE   6.26 (-9.01%)
MU   49.09 (-3.25%)
AMD   76.85 (+2.56%)
T   28.29 (-2.21%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.66 (-2.14%)
NFLX   480.00 (+2.14%)
DIS   124.31 (-3.36%)
BAC   24.12 (-4.32%)
BA   156.69 (-2.76%)
S&P 500   3,245.38 (-2.23%)
DOW   26,869.54 (-2.85%)
QQQ   264.36 (-0.94%)
AAPL   107.14 (+0.28%)
MSFT   200.20 (-0.09%)
FB   248.31 (-1.67%)
GOOGL   1,427.35 (-1.64%)
AMZN   2,904.48 (-1.71%)
NVDA   492.99 (+1.11%)
TSLA   444.47 (+0.52%)
BABA   271.13 (-0.47%)
CGC   15.61 (-4.58%)
GE   6.26 (-9.01%)
MU   49.09 (-3.25%)
AMD   76.85 (+2.56%)
T   28.29 (-2.21%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.66 (-2.14%)
NFLX   480.00 (+2.14%)
DIS   124.31 (-3.36%)
BAC   24.12 (-4.32%)
BA   156.69 (-2.76%)
Log in
NASDAQ:MEDP

Medpace Stock Forecast, Price & News

$108.92
-3.61 (-3.21 %)
(As of 09/21/2020 02:03 PM ET)
Add
Compare
Today's Range
$107.99
Now: $108.92
$110.86
50-Day Range
$115.71
MA: $123.18
$130.61
52-Week Range
$58.72
Now: $108.92
$144.49
Volume14,895 shs
Average Volume340,377 shs
Market Capitalization$3.86 billion
P/E Ratio38.76
Dividend YieldN/A
Beta1.3
Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its drug development services include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Read More
Medpace logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.05 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MEDP
CUSIPN/A
Phone513-579-9911

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$860.97 million
Cash Flow$3.48 per share
Book Value$20.16 per share

Profitability

Net Income$100.44 million

Miscellaneous

Employees3,500
Market Cap$3.86 billion
Next Earnings Date10/26/2020 (Confirmed)
OptionableOptionable
$108.92
-3.61 (-3.21 %)
(As of 09/21/2020 02:03 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MEDP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Medpace (NASDAQ:MEDP) Frequently Asked Questions

How has Medpace's stock been impacted by Coronavirus?

Medpace's stock was trading at $83.64 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MEDP stock has increased by 30.4% and is now trading at $109.10.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Medpace?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Medpace
.

When is Medpace's next earnings date?

Medpace is scheduled to release its next quarterly earnings announcement on Monday, October 26th 2020.
View our earnings forecast for Medpace
.

How can I listen to Medpace's earnings call?

Medpace will be holding an earnings conference call on Monday, October 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Medpace's earnings last quarter?

Medpace Holdings Inc (NASDAQ:MEDP) released its earnings results on Monday, July, 27th. The company reported $0.68 EPS for the quarter, topping the consensus estimate of $0.40 by $0.28. The firm had revenue of $205 million for the quarter, compared to analysts' expectations of $181.17 million. Medpace had a net margin of 12.11% and a return on equity of 16.05%. The firm's quarterly revenue was down 4.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.81 earnings per share.
View Medpace's earnings history
.

What guidance has Medpace issued on next quarter's earnings?

Medpace issued an update on its FY20 earnings guidance on Monday, July, 27th. The company provided earnings per share guidance of $3.62-3.83 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.33. The company issued revenue guidance of $880-920 million, compared to the consensus revenue estimate of $831.87 million.

What price target have analysts set for MEDP?

5 analysts have issued 1-year target prices for Medpace's stock. Their forecasts range from $75.00 to $124.00. On average, they expect Medpace's share price to reach $97.67 in the next year. This suggests that the stock has a possible downside of 10.5%.
View analysts' price targets for Medpace
.

Are investors shorting Medpace?

Medpace saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 1,390,000 shares, a decline of 14.7% from the August 15th total of 1,630,000 shares. Based on an average trading volume of 314,500 shares, the days-to-cover ratio is currently 4.4 days. Approximately 5.1% of the company's stock are sold short.
View Medpace's Short Interest
.

Who are some of Medpace's key competitors?

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), EXACT Sciences (EXAS), JD.Com (JD), Square (SQ), Baidu (BIDU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Bilibili (BILI), Intuitive Surgical (ISRG) and Alteryx (AYX).

Who are Medpace's key executives?

Medpace's management team includes the following people:
  • Dr. August James Troendle, Chairman, Pres & CEO (Age 63)
  • Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 45)
  • Ms. Susan E. Burwig, Exec. VP of Operations (Age 56)
  • Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. Todd Meyers, VP of Bus. Devel. & Marketing

When did Medpace IPO?

(MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.26%), Wasatch Advisors Inc. (7.23%), Pendal Group Ltd (3.04%), Boston Trust Walden Corp (1.11%), Fisher Asset Management LLC (1.01%) and Charles Schwab Investment Management Inc. (0.95%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald and Susan E Burwig.
View institutional ownership trends for Medpace
.

Which major investors are selling Medpace stock?

MEDP stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Vanguard Group Inc., Federated Hermes Inc., Bernzott Capital Advisors, MERIAN GLOBAL INVESTORS UK Ltd, WINTON GROUP Ltd, Sei Investments Co., and AQR Capital Management LLC. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald, and Susan E Burwig.
View insider buying and selling activity for Medpace
.

Which major investors are buying Medpace stock?

MEDP stock was purchased by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, Wasatch Advisors Inc., Charles Schwab Investment Management Inc., Redwood Investments LLC, Nordea Investment Management AB, American Capital Management Inc., ClariVest Asset Management LLC, and Raymond James & Associates.
View insider buying and selling activity for Medpace
.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $109.10.

How big of a company is Medpace?

Medpace has a market capitalization of $3.86 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis. Medpace employs 3,500 workers across the globe.

What is Medpace's official website?

The official website for Medpace is www.medpace.com.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.